Study Finds Link Between Failure of Prostate Cancer Treatments and Cell Reprogramming

A team of researchers led by HICCC members Cory Abate-Shen, PhD and Michael Shen, PhD identified a cellular reprogramming mechanism that reduces response to anti-androgen therapy in some patients with advanced prostate cancer, leading to treatment failure and the development of aggressive disease. The study, published in Cancer Discovery, a journal of the American Association for Cancer Research, provides new approaches to genetically identify patients who are likely to fail anti-androgen therapy.

Read the full story at the CUMC Newsroom.